Shares of IAMGOLD Co. (TSE:IMG – Get Free Report) (NYSE:IAG) have earned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, two have given a buy recommendation and four have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is C$17.80.
IMG has been the topic of several research reports. Cormark boosted their target price on IAMGOLD from C$16.50 to C$20.00 in a research note on Tuesday, September 16th. National Bankshares boosted their target price on IAMGOLD from C$21.00 to C$23.00 and gave the company an “outperform” rating in a research note on Wednesday. Royal Bank Of Canada upgraded IAMGOLD from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, September 10th. Canaccord Genuity Group boosted their target price on IAMGOLD from C$15.50 to C$19.50 in a research note on Thursday, October 2nd. Finally, Bank of America boosted their target price on IAMGOLD from C$13.00 to C$15.50 in a research note on Friday, August 29th.
Get Our Latest Stock Report on IMG
IAMGOLD Trading Up 4.9%
About IAMGOLD
Iamgold Corp is a mid-tier gold mining company operating in three regions globally North America, South America and West Africa. Within these regions, the company is developing potential mining districts that encompass operating mines and construction, development and exploration projects. The company’s operating mines include Essakane in Burkina Faso, Rosebel in Suriname and Westwood in Canada.
Read More
- Five stocks we like better than IAMGOLD
- There Are Different Types of Stock To Invest In
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Stock Dividend Cuts Happen Are You Ready?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for IAMGOLD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IAMGOLD and related companies with MarketBeat.com's FREE daily email newsletter.